ADORA2A and cancer: Preliminary clinical results have reported that some agents [including anti-CD73 antibody, BMS-986179 (29) and CPI-006 (30); A2AR antagonist NIR178 (PBF-509) (31), inupadenant (EOS-850) (32) and Ciforadenant (CPI-444) (1, 33); A2AR/A2BR dual antagonist, AB928 (34, 35)] show good human tolerability and encouraging cancer treatment effects.